ArticleRevista medica del Instituto Mexicano del Seguro Social2026
[Histopathological findings associated with complete clinical remission in patients with lupus nephritis].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus. Patients who do not achieve remission have a 10-year renal survival rate of 19%. Objective: To evaluate the histopathological findings of LN associated with complete remission > 12 months after kidney biopsy. Material and methods: Retrospective cohort of adults with lupus (2019 EULAR/ACR criteria) who underwent kidney biopsy between January 2017 and December 2021. Clinical, biochemical, and histopathological data were collected at the time of biopsy; renal function (serum creatinine, estimated glomerular filtration rate [eGFR], and proteinuria/day) was measured throughout the study (end of follow-up in June 2023). Results: Thirty-eight patients were included. When comparing the non-remission group (n = 13) with the complete remission group (n = 18), only the degree of interstitial fibrosis and tubular atrophy (IFTA) (grade 2: 46% vs. 11%, respectively) and the chronicity index [5.0 (4.0-6.5) vs. 3.0 (1.0-5.0)] showed significant differences (p < 0.05). At the end of the study, the non-remission group, compared with the complete remission group, had lower eGFR [57 (10-100) vs. 104 (87-123) mL/min/1.73 m², p < 0.05] and higher proteinuria [4.00 (1.82-8.00) vs. 0.25 (0.16-0.39) g/day, p < 0.05]. In the logistic regression analysis, only proteinuria [OR 0.72 (95%CI 0.54-0.98), p = 0.03] predicted remission. Conclusions: The histopathological findings associated with complete LN remission > 12 months were lower IFTA and a lower chronicity index. In the multivariate analysis, the only significant variable predicting remission was baseline proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.